A Critical Assessment of Vector Control for Dengue Prevention

Recently, the Vaccines to Vaccination (v2V) program expanded its’ scope, goals, and administration from a focus on vaccines to more integrated and synergistic approaches for the prevention and control of dengue. It is now referred to as the Partnership for Dengue Control (PDC). This shift is consistent with the growing consensus among the dengue prevention community that no single intervention will be sufficient to control dengue and that sustained disease prevention will require integration of multiple intervention strategies.

Objectives

Although the concept of integrated intervention for dengue prevention is broadly accepted, no consensus has been reached regarding the details of how a combination of approaches can be most effectively implemented. To fill that gap a sub-group of the PDC proposed a workshop to convene a multi-disciplinary panel to (1) critically review current and future vector control tools and strategies for dengue prevention and (2) develop a plan for substantially advancing effective application of vector control for dengue prevention, including integration of vector control with other means of dengue prevention.

Download full summary

Speakers & Participants

Group 1: Existing tools & strategies

Discussion Leader: N Achee
Rapporteur: R Reiner

• Duane Gubler, PDC / Duke University
• Rémy Teyssou, PDC
• Dan Stinchcomb, FluGen
• Michael Gottlieb
• T Mclean
• Paul Reiter, Pasteur Institute
• Amy Morrison, University of California
• Scott Ritchie, James Cook University
• Charles Wondji, Liverpool School of Tropical Medicine
• K Campbell, Medical Center / Chula Vista
• Dawn Wesson, Tulane University
• Roberto Barrera, PDC
• Donald Shepard, Brandeis University
• Tom W. Scott, University of California
• James Richardson, Indiana University School of Medicine
• Louise Gresham, Fondation Mérieux USA

Group 2 :Tools & strategies in development

Discussion Leader: F Gould
Rapporteur: A Perkins

• Georges Thiry, DVI
• Lance Gordon, Washington University in Saint Louis
• S James
• Anastasia Pantelias, Bill & Melinda Gates Foundation
• Maria Rosario Capeding, Research Institute for Tropical Medicine (Sanofi)
• Rosalyn B. Beaty, Occupational Medicine Clinic
• Scott O’Niell, Monash University
• H Parry
• Derek Cummings, University of Florida
• Eva Harris, University of Berkeley
• Joachim Hombach, WHO
• Aurélie Malecot-Chabanel, PDC / Alcimed
• Greg Devine, Queensland Institute of Medical Research
• Dagna O. Constenla, Johan Hopkins Bloomberg school of Public health
• N Hammon

Program – Day 1

Current and future prospects for dengue control

Review of the state-of-the-art

• 1 – T Scott: Overview of meeting agenda, goals, and objectives (5 min)
• 2 – Louise Gresham: CEO for Fondation Merieux USA
• 3 – D Gubler: Partnership for Dengue Control
• 4 – G Thiry: Dengue Vaccine Initiative
• 5 – J Hombach: Vector control and the WHO global strategy for dengue prevention
• 6 – T McLean: Framework for intervention validation
• 7 – G Thiry: Overview of dengue vaccines
• 8 – A Morrison: Entomological surveillance
• 9 – S Ritchie: Current vector control tools and practices

New vector control tools and strategies

• 10 – T Scott: Advantages of combining vaccines with vector control
• 11 – C Wondji: Insecticides
• 12 – B Beaty: Molecular insecticides
• 13 – S O’Neill: Wolbachia
• 14 – H Parry: RIDL
• 15 – F Gould: Genetic strategies
• 16 – N Achee: Spatial repellents
• 17 – D Wesson: Lethal ovitraps
• 18 – Open discussion: Other tools and strategies

Concluding remarks and key points for further discussion

Program – Day 2

Mosquito ecology and modeling

• 19 – E Harris: Community-based control
• 20 – R Barrera: Vector ecology and dengue prevention
• 21 – D Cummings: Modeling virus serotype interaction and stain variation
• 22 – D Sheppard: Modeling cost-effectiveness of dengue prevention
• 23 – K Campbell: Predicting surveillance and intervention success

Breakout group objectives

Where are we, where do we need to be, what are the most promising tools and strategies, what needs to be done, and how should next steps be accomplished?

Group 1: Critical assessment of existing vector control tools and strategies

• What vector control tools/approaches are currently available
• What works, why does it work, and under what circumstances does it work
• What does not work and why
• Costs and other delivery challenges
• How can best options be integrated with other interventions

Group 2: Critical assessment of vector control tools and strategies that are currently in development

• What vector control tools/approaches are in development
• What is most promising, how does it work, why should it prevent disease, and under
• what circumstances do we expect it to work
• Steps required prior to broad scale public health application
• Costs and other delivery challenges
• How can best options be integrated with other interventions

Breakout groups resume deliberations

Breakout group summary reports and open discussion Next steps

Closing remarks